Related references
Note: Only part of the references are listed.Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs
Emanuele D'Amico et al.
DRUG SAFETY (2016)
Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial
C. Bozic et al.
EUROPEAN JOURNAL OF NEUROLOGY (2014)
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Gary Bloomgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps
Fariha Zaheer et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2012)
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Kenneth R. Carson et al.
BLOOD (2009)
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis
M. Krumbholz et al.
NEUROLOGY (2008)
Predicting intracranial traumatic findings on computed tomography in patients with minor head injury: The CHIP prediction rule
Marion Smits et al.
ANNALS OF INTERNAL MEDICINE (2007)
Visceral adiposity is an independent predictor of incident hypertension in Japanese Americans
T Hayashi et al.
ANNALS OF INTERNAL MEDICINE (2004)
JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy
IJ Koralnik et al.
JOURNAL OF VIROLOGY (2001)